COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn BHBH FPVFPV FLVFLV PVP-IPI REGNR2 LY-CoVLY RMDRMD
HCQ study #109 of 264
8/5 Late treatment study
Kalligeros et al., Journal of Global Antimicrobial Resistance, doi:10.1016/j.jgar.2020.07.018 (Peer Reviewed)
Hydroxychloroquine use in hospitalised patients with COVID-19: An observational matched cohort study
Source   PDF   Share   Tweet
Small retrospective database analysis of 36 patients receiving HCQ not showing significant differences. Confounding by indication is likely.

Kalligeros et al., 8/5/2020, retrospective, USA, North America, peer-reviewed, 13 authors.
risk of death, 67.0% higher, RR 1.67, p = 0.57, treatment 36, control 72.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 264 studies    Meta analysis
Please send us corrections, updates, or comments.